Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 16/20 | 0.74 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.74 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | IL1B | P01584 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3653462 | 0.91 | CRBN (0.74) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL3654727 | 0.88 | CRBN (0.71) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL13881408 | 0.88 | DDB1 (0.71) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26192402 | 0.88 | CRBN (0.71) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL3654670 | 0.88 | CRBN (0.71) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL4098125 | 0.88 | DDB1 (0.71) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL3649915 | 0.88 | CRBN (0.71) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL3655019 | 0.88 | DDB1 (0.71) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22667820 | 0.88 | CRBN (0.71) | DDB1CRBNIKZF3TNFIL1B | |
| Hydrochloric Acid SCHEMBL18815281 | 0.87 | CRBN (0.70) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-4180432-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| EP-4180427-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| WO-2022111526-A1 | BENZENE RING DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2022-06-02 | — | — | WO | disclosed |
| WO-2022068933-A1 | COMPOUNDS AND METHODS OF TREATING DISEASES | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022047145-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022042707-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022007824-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | 四川海思科制药有限公司 | 2022-01-13 | — | — | WO | disclosed |
| WO-2022007903-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | 四川海思科制药有限公司 | 2022-01-13 | — | — | WO | disclosed |
| US-8492395-B2 | 7-substituted quinazolinone compounds and compositions comprising the same | CELGENE CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492395-B2 | 7-substituted quinazolinone compounds and compositions comprising the same | CELGENE CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492395-B2 | 7-substituted quinazolinone compounds and compositions comprising the same | CELGENE CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2200999-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009075795-A1 | BIOMARKERS FOR MONITORING THE TREATMENT BY QUINAZOLINONE COMPOUNDS | CELGENE CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2009-04-09 | — | — | US | disclosed |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2009-04-09 | — | — | US | disclosed |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2009-04-09 | — | — | US | disclosed |
| WO-2009042177-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009042177-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | AR, CYP17A1, KLK3 | DDB1 4158/4885CRBN 3240/4885IKZF3 3819/4885 |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CYP3A7, CYP2D6, CYP2B6 | DDB1 3263/4885CRBN 3949/4885IKZF3 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.